Citius Oncology (NASDAQ:CTOR - Get Free Report) was downgraded by equities researchers at Maxim Group from a "strong-buy" rating to a "hold" rating in a research note issued on Friday, Marketbeat reports.
Citius Oncology Stock Performance
Shares of CTOR stock opened at $0.91 on Friday. The company has a current ratio of 0.34, a quick ratio of 0.08 and a debt-to-equity ratio of 0.08. The business's 50 day moving average is $0.76 and its two-hundred day moving average is $1.00. Citius Oncology has a 12 month low of $0.55 and a 12 month high of $4.42.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Institutional Investors Weigh In On Citius Oncology
An institutional investor recently bought a new position in Citius Oncology stock. Citadel Advisors LLC bought a new stake in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 22,699 shares of the company's stock, valued at approximately $26,000. Institutional investors and hedge funds own 70.52% of the company's stock.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Featured Articles
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
